BioSenic Puts Fracture Cell Therapy Program on Hold After Mid-Stage Failure

By /

Following disappointing Phase IIb results, BioSenic is pausing the development of its tibial fracture cell therapy ALLOB derived from mesenchymal stem cells.

Scroll to Top